Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis

다국어 초록 (Multilingual Abstract)

Purpose: The aim of the present study was to elucidate the clinicopathological significance and diagnostic accuracy of immunohistochemistry (IHC) for determining the mesenchymal epidermal transition (c-MET) expression in patients with gastric cancer (GC).

Materials and Methods: The present meta-analysis investigated the correlation between c-MET expression as determined by IHC and the clinicopathological parameters in 8,395 GC patients from 37 studies that satisfied the eligibility criteria. In addition, a concordance analysis was performed between c-MET expression as determined by IHC and c-MET amplification, and the diagnostic test accuracy was reviewed.

Results: The estimated rate of c-MET overexpression was 0.403 (95% confidence interval [CI], 0.327~0.484) and it was significantly correlated with male patients, poor differentiation, lymph node metastasis, higher TNM stage, and human epidermal growth factor receptor 2 (HER2) positivity in IHC analysis. There was a significant correlation between c-MET expression and worse overall survival rate (hazard ratio, 1.588; 95% CI, 1.266~1.992). The concordance rates between c-MET expression and c-MET amplification were 0.967 (95% CI, 0.916~0.987) and 0.270 (95% CI, 0.173~0.395) for cases with non-overexpressed and overexpressed c-MET , respectively.

In the diagnostic test accuracy review, the pooled sensitivity and specificity were 0.56 (95% CI, 0.50~0.63) and 0.79 (95% CI, 0.77~0.81), respectively.

Conclusions: The c-MET overexpression as determined by IHC was significantly correlated with aggressive tumor behavior and positive IHC status for HER2 in patients with GC. In addition, the c-MET expression status could be useful in the screening of c-MET amplification in patients with GC.

참고문헌 (Reference)

1 Kubicka S, "p53 mutation pattern and expression of c-erbB2 and cmet in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis" 47 : 114-121, 2002

2 Ishii HH, "p53 is an indicator of tumor progression in early but not advanced gastric carcinomas" 54 : 2159-2163, 2007

3 Bosman FT, "WHO Classification of Tumours of the Digestive System" International Agency for Research on Cancer 2010

4 Zhao J, "Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas" 26 : 1111-1120, 2011

5 Peng Z, "Tumor MET expression and gene amplification in Chinese patients with locally advanced or metastatic gastric or gastroesophageal junction cancer" 14 : 2634-2641, 2015

6 Sun Y, "Tissue microarray analysis of multiple gene expression in intestinal metaplasia, dysplasia and carcinoma of the stomach" 46 : 505-514, 2005

7 Taniguchi K, "The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor" 82 : 2112-2122, 1998

8 Xing X, "The prognostic value of E-cadherin in gastric cancer : a meta-analysis" 132 : 2589-2596, 2013

9 Nakajima M, "The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas" 85 : 1894-1902, 1999

10 Drebber U, "The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation" 19 : 1477-1483, 2008

11 Sotoudeh K, "The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays" 7 : 57-, 2012

12 Aleksandra Paliga, "The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas" Ovid Technologies (Wolters Kluwer Health) 1-, 2015

13 Kang BW, "Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer" 139 : 1835-1843, 2013

14 Gherardi E, "Targeting MET in cancer : rationale and progress" 12 : 89-103, 2012

15 Iveson T, "Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study" 15 : 1007-1018, 2014

16 Garrett JT, "Resistance to HER2-directed antibodies and tyrosine kinase inhibitors : mechanisms and clinical implications" 11 : 793-800, 2011

17 Catenacci DV, "RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma" 12 : 9-46, 2011

18 Ma J, "Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma" 19 : 821-832, 2013

19 Peng Z, "Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis" 9 : e84502-, 2014

20 Kurokawa Y, "Prognostic impact of major receptor tyrosine kinase expression in gastric cancer" 21 (21): S584-S590, 2014

21 Fuse N, "Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients" 19 : 183-191, 2016

22 Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world" 24 : 2137-2150, 2006

23 Huang TJ, "Overexpression of the c-met protooncogene in human gastric carcinoma : correlation to clinical features" 40 : 638-643, 2001

24 Tang Z, "Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia" 11 : 333-339, 2004

25 Han SU, "Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma" 242 : 676-683, 2005

26 Zamora J, "Meta-DiSc : a software for meta-analysis of test accuracy data" 6 : 31-, 2006

27 Metzger ML, "MET in gastric cancer : discarding a 10% cutoff rule" 68 : 241-253, 2016

28 Janjigian YY, "MET expression and amplification in patients with localized gastric cancer" 20 : 1021-1027, 2011

29 Chen CT, "MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells" 11 : 660-669, 2012

30 Koh YW, "Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma" 212 : 93-100, 2016

31 Lee J, "Impact of MET amplification on gastric cancer : possible roles as a novel prognostic marker and a potential therapeutic target" 25 : 1517-1524, 2011

32 Lee KH, "Immunohistochemical analysis of cell cycle-related molecules in gastric carcinoma: prognostic significance, correlation with clinicopathological parameters, proliferation and apoptosis" 75 : 364-372, 2008

33 Zhu C, "Heterogeneity of c-Met expression in Chinese gastric cancer patients" 46 : 1901-1907, 2015

34 Ha SY, "HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression : a distinct subset of patients for dual inhibition therapy" 136 : 1629-1635, 2015

35 Liu YJ, "HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma" 110 : 1169-1178, 2014

36 Gravalos C, "HER2 in gastric cancer : a new prognostic factor and a novel therapeutic target" 19 : 1523-1529, 2008

37 Zhang Z, "Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer" 20 : 4559-4573, 2014

38 Betts G, "FGFR2, HER2 and cMet in gastric adenocarcinoma:detection, prognostic significance and assessment of downstream pathway activation" 464 : 145-156, 2014

39 Parmar MK, "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints" 17 : 2815-2834, 1998

40 Wu JG, "Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma" 7 : 6-, 2014

41 Nagatsuma AK, "Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma" 18 : 227-238, 2015

42 Retterspitz MF, "Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis" 30 : 4635-4641, 2010

43 Lieto E, "Expression of vascular endothelial growth factor(VEGF)and epidermal growth factor receptor(EGFR)is an independent prognostic indicator of worse outcome in gastric cancer patients" 15 : 69-79, 2008

44 Guo T, "Expression of MACC1 and c-Met in human gastric cancer and its clinical significance" 13 : 121-, 2013

45 Yun C, "Essential role of Her3 in two signaling transduction patterns : Her2/Her3 and MET/Her3 in proliferation of human gastric cancer" 54 : 1700-1709, 2015

46 Liu X, "Developing c-MET pathway inhibitors for cancer therapy : progress and challenges" 16 : 37-45, 2010

47 Kim JH, "Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer" 20 : 835-842, 2007

48 Pyo JS, "Concordance rate between HER2immunohistochemistry and in situ hybridization in gastric carcinoma: systematic review and meta-analysis" 31 : e1-e10, 2016

49 Kuboki Y, "Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer" 27 : 127-133, 2016

50 Moses LE, "Combining independent studies of a diagnostic test into a summary ROC curve : dataanalytic approaches and some additional considerations" 12 : 1293-1316, 1993

51 Inokuchi M, "Clinical significance of MET in gastric cancer" 7 : 317-327, 2015

52 Yu S, "C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis" 8 : e79137-, 2013

53 Yusuf S, "Beta blockade during and after myocardial infarction : an overview of the randomized trials" 27 : 335-371, 1985

54 Agarwal S, "Association of constitutively activated hepatocyte growth factor receptor(Met)with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells" 100 : 941-949, 2009

55 Kneissl J, "Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines" 41 : 733-744, 2012

56 Choi J, "Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: its clinical implication and comparison with immunohistochemistry and silver in situ hybridization" 9 : e111658-, 2014

57 Kijima Y, "Amplification and overexpression of c-met gene in Epstein-Barr virus-associated gastric carcinomas" 62 : 60-65, 2002

58 Heideman DA, "Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma" 194 : 428-435, 2001

59 Li Y, "Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma" 106 : 304-310, 2012

60 Lee SJ, "A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma" 33 : 5179-5186, 2013